{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:09:18Z","timestamp":1788800958089,"version":"build-2803163510"},"reference-count":43,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":235,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The clinical management of adrenocortical carcinoma (ACC) has long been defined by its resistance to conventional therapies. Since the FIRM-ACT trial established the combination of etoposide, doxorubicin, and cisplatin plus mitotane (EDP-M) as the frontline standard, overall survival for metastatic patients has remained stubbornly low. This plateau in efficacy with cytotoxic regimes has necessitated a shift towards precision oncology and immunotherapy. However, translating the success of immune checkpoint inhibitors seen in other malignancies to ACC has proven exceptionally difficult. The primary challenge in the present therapeutic landscape of immunotherapy is the unique biology of the adrenal cortex, which creates an intrinsic immunologically privileged site. This review will address these current immunological hurdles but also explore novel strategies designed to bypass this barrier entirely. By shifting focus towards mechanisms that do not solely rely on the traditional engagement of adaptive immune system \u2013 such as the targeted delivery of cytotoxic payloads via antibody\u2013drug conjugates (ADCs) or the androgen-mediated activation of myeloid cells to clear pro-tumoural populations \u2013 the field is moving towards a future where the \u2018cold\u2019 nature of the tumour microenvironment may no longer dictate the limits of therapeutic success.<\/jats:p>","DOI":"10.1530\/eo-26-0040","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:51:51Z","timestamp":1787604711000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":0,"title":["Beyond mitotane: next-generation therapeutic landscapes in adrenocortical carcinoma"],"prefix":"10.1530","volume":"6","author":[{"given":"Keya","family":"Kotecha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Mariniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4616-6044","authenticated-orcid":true,"given":"Leonardo","family":"Guasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"2026090712363867300_bib1","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"2026090712363867300_bib2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"2026090712363867300_bib3","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors","volume":"102","author":"Henning","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026090712363867300_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101434","article-title":"Next-generation therapies for adrenocortical carcinoma","volume":"34","author":"Altieri","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026090712363867300_bib5","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2026090712363867300_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000469","article-title":"Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma","volume":"8","author":"Landwehr","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026090712363867300_bib7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assie","year":"2014","journal-title":"Nat Genet"},{"key":"2026090712363867300_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/cancers18020229","article-title":"Steroid phenotype stratification reveals distinct HLA expression signatures in adrenocortical carcinoma","volume":"18","author":"Giner","year":"2026","journal-title":"Cancers"},{"key":"2026090712363867300_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"2026090712363867300_bib10","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2147\/OTT.S159979","article-title":"Beta-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion","volume":"11","author":"Liu","year":"2018","journal-title":"Onco Targets Ther"},{"key":"2026090712363867300_bib11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-Cell-Inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026090712363867300_bib12","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/beta-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026090712363867300_bib13","doi-asserted-by":"crossref","first-page":"S520","DOI":"10.1016\/j.annonc.2024.08.727","article-title":"661P Safety and activity of CY-101 in patients with advanced solid tumors: the phase I\/IIa CICILIA trial","volume":"35","author":"Sikkema","year":"2024","journal-title":"Ann Oncol"},{"key":"2026090712363867300_bib14","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3390\/cancers13051030","article-title":"Angiogenesis in the normal adrenal fetal cortex and adrenocortical tumors","volume":"13","author":"Pereira","year":"2021","journal-title":"Cancers"},{"key":"2026090712363867300_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fendo.2011.00027","article-title":"Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells","volume":"2","author":"Kroiss","year":"2011","journal-title":"Front Endocrinol"},{"key":"2026090712363867300_bib16","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/cancers17122004","article-title":"The efficacy and safety of multi-kinase inhibitors in adrenocortical carcinoma: a systematic review and single-arm meta-analysis","volume":"17","author":"Flauto","year":"2025","journal-title":"Cancers"},{"key":"2026090712363867300_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026090712363867300_bib18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.36401\/JIPO-25-6","article-title":"Phase 2 study of monotherapy with pembrolizumab for advanced adrenocortical carcinoma","volume":"8","author":"Chahla","year":"2025","journal-title":"J Immunother Precis Oncol"},{"key":"2026090712363867300_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026090712363867300_bib20","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026090712363867300_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026090712363867300_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106030","article-title":"Mismatch repair deficiency and microsatellite instability in adrenocortical carcinoma","volume":"11","author":"Altieri","year":"2026","journal-title":"ESMO Open"},{"key":"2026090712363867300_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54661-9","article-title":"Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat Commun"},{"key":"2026090712363867300_bib24","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1186\/s12885-019-6389-3","article-title":"Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients","volume":"19","author":"Liang","year":"2019","journal-title":"BMC Cancer"},{"key":"2026090712363867300_bib25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ijc.34526","article-title":"FSCN1 as a new druggable target in adrenocortical carcinoma","volume":"153","author":"Ruggiero","year":"2023","journal-title":"Int J Cancer"},{"key":"2026090712363867300_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108948","article-title":"Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity","volume":"35","author":"Wang","year":"2021","journal-title":"Cell Rep"},{"key":"2026090712363867300_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cytogfr.2019.03.006","article-title":"The imprinted gene Delta like non-canonical Notch ligand 1 (Dlk1) is conserved in mammals, and serves a growth modulatory role during tissue development and regeneration through Notch dependent and independent mechanisms","volume":"46","author":"Traustadottir","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026090712363867300_bib28","doi-asserted-by":"crossref","first-page":"R271","DOI":"10.1530\/ERC-21-0208","article-title":"The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer","volume":"28","author":"Pittaway","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"2026090712363867300_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1369\/00221554211048951","article-title":"Emerging roles of DLK1 in the stem cell niche and cancer stemness","volume":"70","author":"Grassi","year":"2022","journal-title":"J Histochem Cytochem"},{"key":"2026090712363867300_bib30","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/cac2.70012","article-title":"Dlk1 is a novel adrenocortical stem\/progenitor cell marker that predicts malignancy in adrenocortical carcinoma","volume":"45","author":"Mariniello","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"2026090712363867300_bib31","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/s41467-025-60649-w","article-title":"Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma","volume":"16","author":"Sun","year":"2025","journal-title":"Nat Commun"},{"key":"2026090712363867300_bib32","first-page":"2","article-title":"Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters","volume":"9","author":"Roth","year":"2026","journal-title":"Cancer Drug Resist"},{"key":"2026090712363867300_bib33","doi-asserted-by":"crossref","first-page":"7828","DOI":"10.3390\/ijms26167828","article-title":"The role of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in cancer stem cell signaling","volume":"26","author":"Jung","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026090712363867300_bib34","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers","volume":"181","author":"Zhang","year":"2012","journal-title":"Am J Pathol"},{"key":"2026090712363867300_bib35","article-title":"ROR-1 specific CAR-T cells with CRISPR\/CAS9 mediated glucocorticoid receptor-knockout exert potent antitumor efficacy in advanced adrenocortical carcinoma","volume":"93","author":"Schauer","year":"2023","journal-title":"Endocr Abstr"},{"key":"2026090712363867300_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","article-title":"Phase I study of ROR1-Specific CAR-T cells in advanced hematopoietic and epithelial malignancies","volume":"31","author":"Jaeger-Ruckstuhl","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026090712363867300_bib37","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1111\/liv.15411","article-title":"DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma","volume":"42","author":"Zhai","year":"2022","journal-title":"Liver Int"},{"key":"2026090712363867300_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add0422","article-title":"Sexually dimorphic activation of innate antitumor immunity prevents adrenocortical carcinoma development","volume":"8","author":"Wilmouth","year":"2022","journal-title":"Sci Adv"},{"key":"2026090712363867300_bib39","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s43587-023-00420-2","article-title":"Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner","volume":"3","author":"Warde","year":"2023","journal-title":"Nat Aging"},{"key":"2026090712363867300_bib40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature25167","article-title":"Senescence-associated reprogramming promotes cancer stemness","volume":"553","author":"Milanovic","year":"2018","journal-title":"Nature"},{"key":"2026090712363867300_bib41","article-title":"Hypogonadism and sexual function in men affected by adrenocortical carcinoma under mitotane therapy","volume":"14","author":"Canu","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026090712363867300_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1128061","article-title":"Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: a single center retrospective longitudinal study","volume":"14","author":"Delbarba","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026090712363867300_bib43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jb\/mvaf001","article-title":"Cellular senescence in the cancer microenvironment","volume":"177","author":"Meguro","year":"2025","journal-title":"J Biochem"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-26-0040\/524161\/eo-26-0040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-26-0040\/524161\/eo-26-0040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:36:57Z","timestamp":1788799017000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/6\/1\/e260040\/78072\/Beyond-mitotane-next-generation-therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-26-0040","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"e260040"}}